Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 17, 2008 - Issue 10
Submit an article Journal homepage
243
Views
43
CrossRef citations to date
0
Altmetric
Drug Evaluation

Treatment of hyperlipidaemia with fenofibrate and related fibrates

Theodosios Filippatos University of Ioannina, School of Medicine, Department of Internal Medicine, 451 10 Ioannina, Greece +30 2651097516; +30 2651097016; [email protected]
, MD PhD &
Haralampos J Milionis University of Ioannina, School of Medicine, Department of Internal Medicine, 451 10 Ioannina, Greece +30 2651097516; +30 2651097016; [email protected]
, MD PhD
Pages 1599-1614 | Published online: 22 Sep 2008

Bibliography

  • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-421
  • Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates. Curr Med Res Opin 2000;16(1):21-32
  • Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849-61
  • Tziomalos K, Athyros VG. Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. Int J Nanomed 2006;1(2):129-47
  • Thorp JM, Waring WS. Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 1962;194:948-9
  • Keating GM, Ormrod D. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002;62(13):1909-44
  • Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997;54(4):615-33
  • Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990;40(2):260-90
  • Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34(2):155-62
  • Desager JP, Costermans J, Verberckmoes R, Harvengt C. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 1982;31(1):51-4
  • Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 2002;24(12):2022-50
  • Munoz A, Guichard JP, Reginault P. Micronised fenofibrate. Atherosclerosis 1994;110(Suppl):S45-8
  • Guichard JP, Blouquin P, Qing Y. A new formulation of fenofibrate: suprabioavailable tablets. Curr Med Res Opin 2000;16(2):134-8
  • Sauron R, Wilkins M, Jessent V, et al. Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation. Int J Clin Pharmacol Ther 2006;44(2):64-70
  • Guivarc'h PH, Vachon MG, Fordyce D. A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions. Clin Ther 2004;26(9):1456-69
  • Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994;58(2):245-7
  • Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301(3):1042-51
  • Ahmad S. Gemfibrozil: interaction with glyburide. South Med J 1991;84(1):102
  • Guay DR. Update on fenofibrate. Cardiovasc Drug Rev 2002;20(4):281-302
  • Kiortsis DN, Nikas S, Hatzidimou K, et al. Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. Fundam Clin Pharmacol 2003;17(4):491-4
  • Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. Am J Med 1987;83(5B):37-43
  • Heady JA, Morris JN, Oliver MF. WHO clofibrate/cholesterol trial: clarifications. Lancet 1992;340(8832):1405-6
  • Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005;165(7):725-30
  • Gonzalez FJ, Peters JM, Cattley RC. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. J Natl Cancer Inst 1998;90(22):1702-9
  • Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405(6785):421-4
  • Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98(19):2088-93
  • Kersten S, Wahli W. Peroxisome proliferator activated receptor agonists. Exs 2000;89:141-51
  • Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998;32(6):1648-56
  • Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med 2001;47:111-36
  • Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18(5):269-76
  • Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37(5):907-25
  • Staels B, Van Tol A, Fruchart JC, Auwerx J. Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Isr J Med Sci 1996;32(6):490-8
  • Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999;10(6):561-74
  • Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95(2):705-12
  • Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001;3(1):83-92
  • Pennacchio LA, Olivier M, Hubacek JA, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001;294(5540):169-73
  • Vu-Dac N, Gervois P, Jakel H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem 2003;278(20):17982-5
  • Shepherd J, Caslake MJ, Lorimer AR, et al. Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 1985;5(2):162-8
  • Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994;111(2):161-74
  • Guerin M, Bruckert E, Dolphin PJ, et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996;16(6):763-72
  • Le Roux CW, Murphy E, Seed M. A retrospective assessment of the effectiveness of fenofibrate 267 mg on high-density lipoprotein cholesterol levels in patients attending a lipid clinic. Clin Ther 2002;24(7):1154-60
  • Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987;83(5B):9-20
  • Hunninghake DB, Peters JR. Effect of fibric acid derivatives on blood lipid and lipoprotein levels. Am J Med 1987;83(5B):44-9
  • Knopp RH, Walden CE, Warnick GR, et al. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E. Am J Med 1987;83(5B):75-84
  • Staels B, Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis 1998;137(Suppl):S19-23
  • Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008;10(6):476-83
  • Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21(1):13-27
  • Kontush A, Chapman MJ. Antiatherogenic small, dense HDL – guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3(3):144-53
  • Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003;23(10):1881-8
  • Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113(12):1556-63
  • Guerin M, Le Goff W, Frisdal E, et al. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003;88(8):3738-46
  • Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today Barc 2006;42(1):39-64
  • Tsimihodimos V, Miltiadous G, Daskalopoulou SS, et al. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3(1):87-98
  • Brown WV, Dujovne CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia. Arteriosclerosis 1986;6(6):670-8
  • Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994;154(4):441-9
  • Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia. Eur J Clin Pharmacol 2000;56(9-10):631-5
  • Bairaktari ET, Tzallas CS, Tsimihodimos VK, et al. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 1999;6(2):113-6
  • Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005;21(12):1997-2006
  • Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193(2):428-37
  • Haubenwallner S, Essenburg AD, Barnett BC, et al. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 1995;36(12):2541-51
  • Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15(19):5336-48
  • Brown WV. Focus on fenofibrate. Hosp Pract (Off Ed) 1988;23(Suppl 1):31-40
  • Feher MD, Caslake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999;15(6):395-9
  • Nielsen LB. Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis 1996;123(1-2):1-15
  • Anber V, Millar JS, McConnell M, et al. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol 1997;17(11):2507-14
  • Krauss RM. Atherogenic lipoprotein phenotype and diet-gene interactions. J Nutr 2001;131(2):S340-3
  • Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003;107(13):1733-7
  • Simo IE, Yakichuk JA, Ooi TC. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis 1993;100(1):55-64
  • Ditschuneit HH, Flechtner-Mors M, Hagel E, Ditschuneit H. Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridaemia: effects of gemfibrozil. J Int Med Res 1992;20(3):197-210
  • Bradford RH, Goldberg AC, Schonfeld G, Knopp RH. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Atherosclerosis 1992;92(1):31-40
  • Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998;19(Suppl A):A24-30
  • Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998;81(7):912-7
  • Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001;357(9260):905-10
  • Steiner G. The use of fibrates and of statins in preventing atherosclerosis in diabetes. Curr Opin Lipidol 2001;12(6):611-7
  • Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005;54(8):1065-74
  • Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25(7):1198-202
  • Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003;44(5):927-34
  • Insua A, Massari F, Rodriguez Moncalvo JJ, et al. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract 2002;8(2):96-101
  • Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003;171(1):1-13
  • Badiou S, Merle De Boever C, Dupuy AM, et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004;172(2):273-9
  • Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002;30(1):26-31
  • Badiou S, Merle De Boever C, Dupuy AM, et al. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis 2003;168(1):107-13
  • Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12(7):F51-8
  • Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003;17(6):851-9
  • Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005;21(9):757-67
  • Skolnik PR, Rabbi MF, Mathys JM, Greenberg AS. Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects. J Acquir Immune Defic Syndr 2002;31(1):1-10
  • Idzior-Walus B, Sieradzki J, Rostworowski W, et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest 2000;30(10):871-8
  • Guerre-Millo M, Gervois P, Raspe E, et al. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 2000;275(22):16638-42
  • Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005;11(32):4161-75
  • Feher MD, Hepburn AL, Hogarth MB, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003;42(2):321-5
  • Achimastos A, Liberopoulos E, Nikas S, et al. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 2002;18(2):59-63
  • Milionis HJ, Elisaf MS. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. Curr Med Res Opin 2000;16(3):164-70
  • Liamis G, Bairaktari ET, Elisaf MS. Effect of fenofibrate on serum uric acid levels. Am J Kidney Dis 1999;34(3):594
  • Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999;34(1):60-3
  • Kiortsis DN, Elisaf MS. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. Fundam Clin Pharmacol 2001;15(6):401-3
  • Mikhailidis DP, Ganotakis ES, Spyropoulos KA, et al. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int Angiol 1998;17(4):225-33
  • Neve BP, Corseaux D, Chinetti G, et al. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001;103(2):207-12
  • Kon Koh K, Yeal Ahn J, Hwan Han S, et al. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 2004;174(2):379-83
  • Durrington PN, MacKness MI, Bhatnagar D, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998;138(1):217-25
  • Ye P, He YL, Wang Q, Liu YX. The alteration of plasminogen activator inhibitor-1 expression by linoleic acid and fenofibrate in HepG2 cells. Blood Coagul Fibrinolysis 2007;18(1):15-9
  • Dong C, Hu Y, Wang H, et al. Inhibitory effects of fenofibrate on plasminogen activator inhibitor-1 expression in human endothelial cells. J Huazhong Univ Sci Technolog Med Sci 2006;26(2):192-3, 8
  • Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22(5):717-26
  • Madej A, Okopien B, Kowalski J, et al. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int J Clin Pharmacol Ther 1998;36(6):345-9
  • Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998;393(6687):790-3
  • Kleemann R, Gervois PP, Verschuren L, et al. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 2003;101(2):545-51
  • Wang TD, Chen WJ, Lin JW, et al. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003;170(2):315-23
  • Okopien B, Krysiak R, Kowalski J, et al. The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 2004;176(2):327-35
  • Marx N, Sukhova GK, Collins T, et al. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99(24):3125-31
  • Ikewaki K, Tohyama J, Nakata Y, et al. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men – a nuclear magnetic resonance study. J Atheroscler Thromb 2004;11(5):278-85
  • Tsimihodimos V, Kostoula A, Kakafika A, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004;9(1):27-33
  • Gervois P, Fruchart JC, Staels B. Inflammation, dyslipidaemia, diabetes and PPars: pharmacological interest of dual PPARalpha and PPARgamma agonists. Int J Clin Pract 2004;58(143):22-9
  • Koh KK, Han SH, Quon MJ, et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005;28(6):1419-24
  • Undas A, Celinska-Lowenhoff M, Domagala TB, et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost 2005;94(1):193-9
  • Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial – FAT). Cardiovasc Res 2001;52(2):290-8
  • Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007;27(10):2236-43
  • Inoue I, Goto S, Matsunaga T, et al. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+, Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 2001;50(1):3-11
  • Iglarz M, Touyz RM, Amiri F, et al. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 2003;23(1):45-51
  • Beltowski J, Wojcicka G, Mydlarczyk M, Jamroz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol 2002;53(3):463-75
  • Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant 2001;16(6):1301
  • Tsimihodimos V, Bairaktari E, Elisaf M. Fibrate-induced increase in serum urea and creatinine levels. Nephrol Dial Transplant 2002;17(4):682; author reply
  • Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000;15(12):1993-9
  • Tsimihodimos V, Miltiadous G, Bairaktari E, Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 2002;57(5):407-8
  • Giral P, Bruckert E, Jacob N, et al. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 2001;154(2):421-7
  • Bissonnette R, Treacy E, Rozen R, et al. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis 2001;155(2):455-62
  • Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 2001;358(9275):39-40
  • Milionis HJ, Papakostas J, Kakafika A, et al. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003;43(8):825-30
  • Dierkes J, Westphal S, Kunstmann S, et al. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate. Atherosclerosis 2001;158(1):161-4
  • Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317(20):1237-45
  • Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992;85(1):37-45
  • Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15(7):820-5
  • Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96(7):2137-43
  • De Faire U, Ericsson CG, Grip L, et al. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996;17(Suppl F):37-42
  • Haim M, Benderly M, Brunner D, et al. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999;100(5):475-82
  • Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341(6):410-8
  • Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002;162(22):2597-604
  • Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370(9600):1687-97
  • Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997;80(5):608-13
  • Guay DR. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother 1999;33(10):1083-103
  • Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40(3):567-72
  • Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol 2002;89(4):390-4
  • Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289(13):1681-90
  • Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005;95(1):120-2
  • Telford M. Clinical pharmacokinetics of fenofibrate. Curr Med Res Opin 2003;19(2):139; author reply -40
  • Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk 2002;9(1):33-9
  • Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95(4):462-8
  • Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91(8):956-60
  • Athyros VG, Papageorgiou AA, Kontopoulos AG. Statin-fibrate combinations in patients with combined hyperlipedemia. Atherosclerosis 2001;155(1):263-4
  • Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59
  • Buse JB, Bigger JT, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99(12A):i21-33
  • Farnier M, Freeman MW, MacDonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26(9):897-905
  • McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005;21(9):1403-12
  • Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of a novel fibrate, ABT-335, in Combination with atorvastatin in patients with mixed dyslipidemia: a 12-week phase 3 study. J Am Coll Cardiol 2008;51(10 Suppl A):222
  • Mohiuddin SM, Pepine CJ, Kelly MT, et al. Efficacy and safety of a novel fibrate, ABT-335, in combination with simvastatin in patients with mixed dyslipidemia: a phase three study. J Am Coll Cardiol 2008;51(10 Suppl A):223
  • Davidson MH, Carlson DM, Guthrie RM, et al. ABT-335 in combination with rosuvastatin improves multiple lipid ratios in patients with mixed dyslipidemia. J Clin Lipidol 2008;2(3):211-2

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.